Novel carboxypeptidase A6 (CPA6) mutations identified in patients with juvenile myoclonic and generalized epilepsy

Matthew R Sapio1, Monique Vessaz2, Pierre Thomas3

  • 1Department of Neuroscience, Albert Einstein College of Medicine, Bronx, NY, United States of America.

Plos One
|April 16, 2015
PubMed

Insights

Two novel Carboxypeptidase A6 (CPA6) mutations, Arg36His and Asn271Ser, are linked to generalized epilepsy. These genetic alterations impair CPA6 enzyme activity and extracellular matrix levels, suggesting a role in epilepsy predisposition.

Area of Science:

  • Biochemistry and Molecular Biology
  • Neurogenetics
  • Enzymology

Background:

  • Carboxypeptidase A6 (CPA6) is a secreted peptidase involved in extracellular matrix processing, with expression in the brain.
  • Previous studies linked CPA6 gene mutations to temporal lobe epilepsy and febrile seizures.
  • The role of CPA6 in generalized epilepsy syndromes remained largely unexplored.

Purpose of the Study:

  • To investigate the potential role of CPA6 mutations in juvenile myoclonic epilepsy (JME).
  • To identify and characterize novel CPA6 variants in epilepsy patients.
  • To assess the functional impact of identified mutations on CPA6 activity and localization.

Main Methods:

  • Screening of CPA6 gene in patients with juvenile myoclonic epilepsy.
  • In silico modeling of identified mutations (Arg36His, Asn271Ser) within the CPA6 structure.
  • In vitro expression studies in HEK293T cells to assess enzyme activity, extracellular matrix (ECM) levels, and secretion kinetics via pulse-chase experiments.

Main Results:

  • Two novel missense mutations, Arg36His and Asn271Ser, were identified in patients with generalized epilepsy, including JME.
  • The Asn271Ser mutation completely abolished CPA6 enzymatic activity.
  • The Arg36His mutation reduced CPA6 levels in the ECM by approximately 50% and decreased overall ECM-associated CPA6.
  • Secretion kinetics were similar for wild-type and mutant CPA6, but total secreted amounts were reduced for mutants.

Conclusions:

  • The identified CPA6 mutations (Arg36His and Asn271Ser) are deleterious and associated with generalized epilepsy.
  • Asn271Ser and Arg36His mutations impair CPA6 function through distinct mechanisms: loss of enzymatic activity and reduced ECM localization, respectively.
  • These findings strengthen the evidence implicating CPA6 gene mutations in the predisposition to various epilepsy types.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.4K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.8K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.0K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.8K